Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Accounts Payables · Q4 FY2026 · quarter ended Sep 2026

Accounts payables turns positive

Q4 FY2026 accounts payables was $2.5M, compared with -$15.38M a year earlier. Trailing-twelve-month accounts payables was $14.67M. Over 3 fiscal years it compounded at -27.7% a year.

Context

  • Accounts payables amounted to 2.8% of revenue in FY2026, up 2.0 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near $2.5M or moves back toward the trailing-twelve-month quarterly average of $3.67M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.5M+180.7% QoQ
Last fiscal yearSep 2026
$12.48M+98.5% YoY
LTMSep 2026
$14.67M+133.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+116.2%——
1 year+98.5%——
3-year CAGR-27.7%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2026
12.48M USD
Year-over-year change
+98.5%

Accounts Payables vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +133.3% is the highest of 5, against a peer median of -46.4%.
  • Accounts payables amounts to 3.3% of revenue for ARWR, versus a peer median of 3.1%.
ARWR Competitors
Accounts Payables for ARWR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$65.76M USD-237.3%-26.8%1.4%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$14.67M USD+133.3%-27.7%3.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$11.71M USD-66.8%—1.2%
SLNSilence Therapeutics plcLTM Mar 2026$5.6M USD——608.1%
WVEWave Life Sciences Ltd.LTM Mar 2026$4.81M USD+99.3%—6.7%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.19M USD-26.1%-1.7%4.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR——0.0%
Peer median (excluding ARWR) —-46.4%-14.3%3.1%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Net Income(176.49M)(209.28M)(609.69M)30.11M(717.13M)
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
Deferred Income Tax00000
Stock-Based Compensation120.89M78.13M73.97M63.37M68.15M
Change in Working Capital(98.29M)(51.55M)25.09M(18.24M)60.9M
Accounts Receivables8.85M1.41M0(56.97M)(3.29M)
Inventory0000(9.08M)
Accounts Payables(6.59M)33M(5.54M)6.29M12.48M
Other Working Capital(100.55M)(85.96M)30.63M32.45M60.78M
Other Non-Cash Items7.34M16.31M29.19M80.38M289.52M
Operating Cash Flow(136.13M)(153.89M)(462.85M)179.55M(271.95M)
Capital Expenditures(52.78M)(176.74M)(141.47M)(22.67M)(12M)
Acquisitions (Net)00000
Purchases of Investments(223.39M)(246.14M)(720.95M)(796.26M)(1.14B)
Sales of Investments270.75M326.72M442.34M689.63M695.23M
Other Investing Activities0000(215M)
Investing Cash Flow(5.42M)(96.16M)(420.07M)(129.29M)(670.48M)
Debt Repayment00392M(191.37M)578.52M
Common Stock Issued5.19M3.05M431.65M270.37M305.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities60M250M46.87M(5M)(107.12M)
Financing Cash Flow65.19M253.05M870.52M74.01M776.82M
Effect of Forex Changes(67K)(122K)4.2M(401K)1.8M
Net Change in Cash(76.43M)2.89M(8.21M)123.86M(163.81M)
Free Cash Flow(188.91M)(330.63M)(604.32M)156.89M(283.94M)

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.